Evidence map›Paper›PMID 41023871›Full record

ArticleBMC cancer2025

Pan-cancer analysis of the oncogenic role of ZNF703 in regulating tumor immunity.

Xianli Shi, Jingyu Lie, Rui Li, Haoming Chen, Rongxin Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xianli Shi *Department of Biochemistry, School of Basic Medical Science, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Jingyu Lie *Guangdong Provincial Key Laboratory of Advanced Drug Delivery, Department of Biotechnology, Laboratory of Immunology and Inflammation, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Rui LiGuangdong Provincial Key Laboratory of Advanced Drug Delivery, Department of Biotechnology, Laboratory of Immunology and Inflammation, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Haoming ChenGuangdong Provincial Key Laboratory of Advanced Drug Delivery, Department of Biotechnology, Laboratory of Immunology and Inflammation, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Rongxin ZhangGuangdong Provincial Key Laboratory of Advanced Drug Delivery, Department of Biotechnology, Laboratory of Immunology and Inflammation, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, 510006, China. rxzhang@gdpu.edu.cn.

Funding

Medical Science and Technology Research Fund of Guangdong province A2025170
6 · The paper itself

Abstract

ZNF703, a member of the NET/NLZ family, plays a critical role in individual development and cancer progression. Despite its significance, a comprehensive pan-cancer analysis of ZNF703 remains underexplored. In this study, we performed a systematic pan-cancer analysis to elucidate the mechanistic and functional roles of ZNF703 in tumorigenesis. Our findings reveal that elevated ZNF703 expression is significantly correlated with cancer progression, adverse clinical outcomes, and the enrichment of immune cells within the tumor microenvironment (TME), particularly cancer-associated fibroblasts (CAFs), CD8

Indexed as

Carrier ProteinsNeoplasmsBiomarkers, TumorCancer-Associated FibroblastsCarcinogenesisGene Expression Regulation, NeoplasticHumansPrognosisTumor MicroenvironmentBiomarkers, TumorCarrier ProteinsCD274CXCL3ICAM1Tumor immunityZNF703

Identifiers

PMID41023871
PMCPMC12482501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.